FDA label
What is Nexlizet used for?
Nexlizet contains bempedoic acid and ezetimibe. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH); to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for th...”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Nexlizet?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Nexlizet, tablet, film coated
Indications and Usage, quoted from the label by Esperion Therapeutics, Inc. (NDA211617). Cross-references to other label sections are left out.
NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated:
- as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
Bempedoic acid, a component of NEXLIZET, is indicated:
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin).
Source: DailyMed label, set id 3fa2108c-0300-47b8-9d34-f762af7c93c6, version 23, effective June 25, 2026. NDC 72426-818, one of 1 listing for this product.
Questions
What is Nexlizet used for?
The FDA label says: “NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH); to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for th...”
What drug class is Nexlizet?
FDA lists bempedoic acid and ezetimibe in the Adenosine Triphosphate-Citrate Lyase Inhibitor and Dietary Cholesterol Absorption Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.